Subpopulations (absolute numbers) | Patients with RMS (favorable localization of the primary tumor) | Control group | Р |
CD3+ HLADR+ | 5.5 ± 1.8 (n = 3) | 2.5 ± 0.6 (n = 11) | 0.047 |
CD8+ HLADR+ | 4.4 ± 1.6 (n = 2) | 1.8 ± 0.4 (n = 10) | 0.048 |